Home LiteratureArticle Details
PMID: 20444756 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.

Annals of the rheumatic diseases ·Vol. 69 ·No. 11 ·2010-11-00 ·Pages 1920-5

Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD

Abstract

Cardiovascular (CV) disease has a major impact on patients with rheumatoid arthritis (RA), however, the relative contributions of traditional CV risk factors and markers of RA severity are unclear. The authors examined the relative importance of traditional CV risk factors and RA markers in predicting CV events. A prospective longitudinal cohort study was conducted in the setting of the CORRONA registry in the USA. Baseline data from subjects with RA enrolled in the CORRONA registry were examined to determine predictors of CV outcomes, including myocardial infarction, stroke or transient ischemic attack. Possible predictors were of two types: traditional CV risk factors and markers of RA severity. The discriminatory value of these variables was assessed by calculating the area under the receiver operating characteristic curve (c-statistic) in logistic regression. The authors then assessed the incidence rate for CV events among subjects with an increasing number of traditional CV risk factors and/or RA severity markers. The cohort consisted of 10 156 patients with RA followed for a median of 22 months. The authors observed 76 primary CV events during follow-up for a composite event rate of 3.98 (95% CI 3.08 to 4.88) per 1000 patient-years. The c-statistic improved from 0.57 for models with only CV risk factors to 0.67 for models with CV risk factors plus age and gender. The c-statistic improved further to 0.71 when markers of RA severity were also added. The incidence rate for CV events was 0 (95% CI 0 to 5.98) for persons without any CV risk factors or markers of RA severity, while in the group with two or more CV risk factors and three or more markers of RA severity the incidence was 7.47 (95% CI 4.21 to 10.73) per 1000 person-years. Traditional CV risk factors and markers of RA severity both contribute to models predicting CV events. Increasing numbers of both types of factors are associated with greater risk.

MeSH Terms
Age Factors Aged Arthritis, Rheumatoid/complications,epidemiology Cardiovascular Diseases/epidemiology,etiology Epidemiologic Methods Female Humans Male Middle Aged Sex Factors United States/epidemiology
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Solomon Daniel H
Brigham and Women's Hospital, Boston Massachusetts 02115, USA. [email protected]
Kremer Joel
Curtis Jeffrey R
Hochberg Marc C
Reed George
Tsao Peter
Farkouh Michael E
Setoguchi Soko
Greenberg Jeffrey D
References (38)
38 references, click to expand
  1. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.
    Hypertension. 2007 Jan;49(1):69-75 PMID: 17159087
  2. Patterns of cardiovascular risk in rheumatoid arthritis.
    Ann Rheum Dis. 2006 Dec;65(12):1608-12 PMID: 16793844
  3. European biologicals registers: methodology, selected results and perspectives.
    Ann Rheum Dis. 2009 Aug;68(8):1240-6 PMID: 18647854
  4. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Arthritis Rheum. 2007 Sep;56(9):2905-12 PMID: 17763428
  5. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.
    Arthritis Rheum. 2002 Aug;46(8):2010-9 PMID: 12209502
  6. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation.
    J Rheumatol. 2001 May;28(5):982-9 PMID: 11361226
  7. Cardiovascular morbidity and mortality in rheumatoid arthritis.
    Am J Med. 2008 Oct;121(10 Suppl 1):S9-14 PMID: 18926169
  8. The CORRONA database.
    Autoimmun Rev. 2006 Jan;5(1):46-54 PMID: 16338211
  9. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.
    J Rheumatol. 2003 Jan;30(1):36-40 PMID: 12508387
  10. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis.
    J Rheumatol. 2003 Jul;30(7):1403-5 PMID: 12858433
  11. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors.
    Arthritis Rheum. 2005 Oct;52(10):3045-53 PMID: 16200609
  12. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
    Lancet. 2004 Jun 19;363(9426):2015-21 PMID: 15207950
  13. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
    Arthritis Rheum. 2008 Sep;58(9):2612-21 PMID: 18759273
  14. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
    Arthritis Rheum. 2006 Dec;54(12):3790-8 PMID: 17136752
  15. Prediction of coronary heart disease using risk factor categories.
    Circulation. 1998 May 12;97(18):1837-47 PMID: 9603539
  16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
    Circulation. 2002 Dec 17;106(25):3143-421 PMID: 12485966
  17. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
    Circulation. 2003 Mar 11;107(9):1303-7 PMID: 12628952
  18. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation.
    Ann Rheum Dis. 2009 Sep;68(9):1395-400 PMID: 18697775
  19. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis.
    Arthritis Rheum. 2005 Nov;52(11):3413-23 PMID: 16255018
  20. Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey.
    J Rheumatol. 2005 Dec;32(12):2311-6 PMID: 16331755
  21. Use and misuse of the receiver operating characteristic curve in risk prediction.
    Circulation. 2007 Feb 20;115(7):928-35 PMID: 17309939
  22. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
    N Engl J Med. 2008 Nov 20;359(21):2195-207 PMID: 18997196
  23. Composite scoring--methods and predictive validity: insights from the Framingham Study.
    Health Serv Res. 1987 Oct;22(4):499-535 PMID: 3679841
  24. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
    Arthritis Rheum. 2005 Feb;52(2):402-11 PMID: 15693010
  25. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.
    Arthritis Res Ther. 2005;7(4):R796-806 PMID: 15987481
  26. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.
    Circulation. 2002 Oct 22;106(17):2184-7 PMID: 12390945
  27. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis.
    J Rheumatol. 2007 May;34(5):943-51 PMID: 17444592
  28. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.
    Lancet. 1999 May 8;353(9164):1547-57 PMID: 10334252
  29. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
    BMJ. 1994 Jan 8;308(6921):81-106 PMID: 8298418
  30. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    Arthritis Res Ther. 2006;8(5):R151 PMID: 16984661
  31. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
    Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8 PMID: 16273793
  32. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.
    JAMA. 1993 Jun 16;269(23):3009-14 PMID: 8501843
  33. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort.
    Arthritis Rheum. 2005 Aug;52(8):2293-9 PMID: 16052597
  34. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.
    Ann Rheum Dis. 2005 Nov;64(11):1595-601 PMID: 15843450
  35. Model selection for extended quasi-likelihood models in small samples.
    Biometrics. 1995 Sep;51(3):1077-84 PMID: 7548692
  36. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects.
    Arthritis Rheum. 2003 Jul;48(7):1833-40 PMID: 12847676
  37. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.
    Ann Rheum Dis. 2010 Feb;69(2):325-31 PMID: 19773290
  38. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.
    Lancet. 2002 Apr 6;359(9313):1173-7 PMID: 11955534
Article Info
Journal
Annals of the rheumatic diseases
Abbr.
Ann Rheum Dis
ISSN
1468-2060
Published
2010-11-00
Epub
2010-00-05
Pages
1920-5
Language
English
Region
England
NLM ID
0372355
PMCID
PMC2963658
Subset
IM
Grants
NIAMS NIH HHS · K24 AR055989-04 · United States
NIAMS NIH HHS · P60 AR047782-06A10006 · United States
NIAMS NIH HHS · K24 AR055989-02 · United States
NIAMS NIH HHS · K23 AR053351-04 · United States
NIAMS NIH HHS · K23 AR054412-05 · United States
NHLBI NIH HHS · U01 HL071988-01A1 · United States
NIAMS NIH HHS · K23 AR053351 · United States
NIAMS NIH HHS · P60 AR047782-090006 · United States
NIAMS NIH HHS · P60 AR047782-080006 · United States
NIAMS NIH HHS · K24 AR055989-03 · United States
NHLBI NIH HHS · U01 HL071988 · United States
NHLBI NIH HHS · R01 HL092989-02 · United States
NHLBI NIH HHS · HL092989 · United States
NIAMS NIH HHS · AR 047782 · United States
NIAMS NIH HHS · K23 AR053351-03 · United States
NIAMS NIH HHS · K24 AR055989-01 · United States
NIAMS NIH HHS · P60 AR047782 · United States
NHLBI NIH HHS · R01 HL092989 · United States
NIAMS NIH HHS · K24 AR055989 · United States
NHLBI NIH HHS · HL071988 · United States
NIAMS NIH HHS · AR053351 · United States
NIAMS NIH HHS · AR055989 · United States
NIAMS NIH HHS · K23 AR053351-03S1 · United States
NIAMS NIH HHS · P60 AR047782-070006 · United States
NIAMS NIH HHS · K23 AR054412 · United States
NIAMS NIH HHS · K23 AR053351-01A1 · United States
NIAMS NIH HHS · K23 AR053351-02 · United States
NIAMS NIH HHS · K23AR054412 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]